Lundbeck/Takeda's Brintellix prospects rise on new data
This article was originally published in Scrip
Executive Summary
Lundbeck's novel multi-modal antidepressant Brintellix (vortioxetine) is set to receive a boost from new clinical data reinforcing its benefits on cognitive function and sexual dysfunction, analysts say.